Home/Pipeline/TAH3311

TAH3311

Anticoagulation (Apixaban)

Phase 3Active

Key Facts

Indication
Anticoagulation (Apixaban)
Phase
Phase 3
Status
Active
Company

About TAHO Pharmaceuticals

TAHO Pharma delivers novel transdermal and oral‑film drug formats to address unmet patient needs across cardiovascular, neurology, and oncology markets.

View full company profile